Yahoo Finance

Sonnet BioTherapeutics Announces Publication Detailing the Discovery and Development of SON-1010, an Albumin-Binding IL-12 Fusion Protein, Demonstrating Its Mechanism of Action

PRINCETON, NJ, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (the "Company" or "Sonnet”) (NASDAQ: SONN), a clinical-stage company developing innovative targeted ...
Nasdaq

Sonnet BioTherapeutics announces publication on SON-1010 development

Sonnet BioTherapeutics (SONN) announced the publication of extensive discovery, development and preclinical data on SON-1010 demonstrating its mechanism of action in Frontiers in Immunology. SON-1010, ...
Yahoo Finance

Sonnet Chief Medical Officer, Richard Kenney, M.D., to Present at the 6th Annual Cytokine-Based Drug Development Summit

Exploring the strategy behind the introduction of receptor bias to reduce toxicity and improve efficacy; Key strategies for optimizing cytokine potency and mitigating their inherent toxicity while ...
Business Wire

RELIEF THERAPEUTICS Holding SA Announces Divestment of its Subsidiary Relief Therapeutics SA to Sonnet BioTherapeutics, Inc. to Ensure the Development of Atexakin Alpha ...

GENEVA--(BUSINESS WIRE)--RELIEF THERAPEUTICS Holding SA (SIX-RLF, “Relief” or the “Company”) announces today that it has executed a binding Share Exchange Agreement (the “Agreement”) with Sonnet ...
Stockhouse

Sonnet BioTherapeutics Announces Publication Detailing the Discovery and Development of SON-1010, an Albumin-Binding IL-12 Fusion Protein, Demonstrating Its Mechanism of Action

PankajMohan, CEO of Sonnet discusses what this publication means in a Virtual Investor “What This Means” segment; access here PRINCETON, NJ, Dec. 04, 2024 (GLOBE NEWSWIRE) -- ...